Zoetis Inc. (ZTS)

Market Cap	67.64B
Revenue (ttm)	8.54B
Net Income (ttm)	2.34B
Shares Out	457.87M
EPS (ttm)	5.07
PE Ratio	29.57
Forward PE	25.62
Dividend	$1.73 (1.17%)
Ex-Dividend Date	Apr 18, 2024

Volume	1,131,267
Open	151.50
Previous Close	153.11
Day's Range	147.12 - 151.54
52-Week Range	147.12 - 201.92
Beta	0.85
Analysts	Strong Buy
Price Target	223.00 (+51.0%)
Earnings Date	May 2, 2024

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 14,100
• Stock Exchange: NYSE
• Ticker Symbol: ZTS

Financial Performance

In 2023, Zoetis's revenue was $8.54 billion, an increase of 5.74% compared to the previous year's $8.08 billion. Earnings were $2.34 billion, an increase of 10.88%.

Analyst Forecast

According to 7 analysts, the average rating for ZTS stock is "Strong Buy." The 12-month stock price forecast is $223.0, which is an increase of 51.00% from the latest price.

Price Target

$223.0

(51.00% upside)

Analyst Consensus: Strong Buy